EUCTR2004-002376-42-IT进行中（未招募）不适用
PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER
G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST0 个研究点目标入组 36 人开始时间: 2006年4月21日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16
进行中（未招募）
不适用
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL.EUCTR2008-001421-34-ATniversität zu Köln16
招募中
Unknown
Randomized phase II study of chemoimmunotherapy with or without metformin as a first-line treatment in patients with squamous cell lung carcinomaNeoplasmsKCT0008659ational Cancer Center70
进行中（未招募）
不适用
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemiaEUCTR2005-000174-52-ITASSOCIAZIONE MALATTIE SANGUE
进行中（未招募）
1 期
Study of chemotherapy and immunotherapy before and after surgery inpatients with non-small cell lung cancer whose tumor is located in theupper part of the lungsCTIS2024-512359-19-00Fundacion GECP40